EUVIMEDEUVIMED entdecken
Crossref

Administration of vadadustat for anemia of chronic kidney disease; an updated review

Sajad Ataei Azimi, Asaad Abass Fadhel Khalif, Ahmadreza Siyasari, Zahra Bazargani, Peyman Khajehnabi, Sara Ghaseminejad Kermani, Kamran Safa, Shirin Shamsghahfarokhi

Journal of Nephropharmacology · 17.08.2025 · 15 (1) · e12806

DOI: 10.34172/npj.2025.12806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nephropharmacology, online erschienen am 17.08.2025. Verfasst von Sajad Ataei Azimi und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a global health burden, often complicated by anemia due to impaired erythropoietin production and iron dysregulation. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), has emerged as a promising therapeutic option for managing anemia in CKD patients. By stabilizing hypoxia-inducible factors, vadadustat enhances endogenous erythropoietin production and improves iron metabolism, offering a novel approach to treating CKD-associated anemia. Recent clinical trials demonstrate that vadadustat effectively increases hemoglobin levels, reduces the need for erythropoiesis-stimulating agents (ESAs), and improves patients’ quality of life. However, concerns regarding its safety, including potential risks of thromboembolic events and hypertension, warrant careful patient selection and monitoring. Comparative analyses with standard therapies, such as ESAs and other HIF-PH inhibitors, highlight vadadustat’s advantages in terms of oral administration and cost-effectiveness, while also identifying areas for further research.

Zitieren

APA

Azimi, S. A., Khalif, A. A. F., Siyasari, A., Bazargani, Z., Khajehnabi, P., Kermani, S. G., Safa, K., & Shamsghahfarokhi, S. (2025). Administration of vadadustat for anemia of chronic kidney disease; an updated review. Journal of Nephropharmacology, 15(1), e12806. https://doi.org/10.34172/npj.2025.12806

Vancouver

Azimi SA, Khalif AAF, Siyasari A, Bazargani Z, Khajehnabi P, Kermani SG, et al. Administration of vadadustat for anemia of chronic kidney disease; an updated review. Journal of Nephropharmacology. 2025;15(1):e12806. doi:10.34172/npj.2025.12806

BibTeX
@article{Azimi2025,
  author = {Azimi, Sajad Ataei and Khalif, Asaad Abass Fadhel and Siyasari, Ahmadreza and Bazargani, Zahra and Khajehnabi, Peyman and Kermani, Sara Ghaseminejad and Safa, Kamran and Shamsghahfarokhi, Shirin},
  title = {Administration of vadadustat for anemia of chronic kidney disease; an updated review},
  journal = {Journal of Nephropharmacology},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {e12806},
  doi = {10.34172/npj.2025.12806}
}
Kostenlos starten →